Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on May 8, 2013. The report announces the financial and operating results for the quarter ended March 31, 2013. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1), which is not part of the input text.
Material Changes
The filing does not provide specific data regarding material changes versus the prior comparable period. It serves only as a notification that the quarterly results have been issued.
Guidance, Outlook, and Risks
The text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. It explicitly states that the information in this report and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly set forth.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., as the input metadata incorrectly listed Altimmune, Inc.
- Locate and review Exhibit 99.1 (the press release dated May 8, 2013) to obtain actual financial figures for the quarter ended March 31, 2013.
- Confirm the legal status of the press release information, noting the disclaimer regarding Section 18 liabilities.